CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 3,590,000 shares, an increase of 8.1% from the March 31st total of 3,320,000 shares. Based on an average daily volume of 905,200 shares, the short-interest ratio is currently 4.0 days.
CytomX Therapeutics Trading Up 1.2 %
CytomX Therapeutics stock traded up $0.02 on Tuesday, hitting $1.63. 341,417 shares of the stock traded hands, compared to its average volume of 809,398. CytomX Therapeutics has a 1 year low of $1.04 and a 1 year high of $2.86. The firm has a market cap of $110.40 million, a P/E ratio of -81.46 and a beta of 1.01. The business's fifty day simple moving average is $2.06 and its 200 day simple moving average is $1.65.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its quarterly earnings results on Monday, March 11th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.01). The company had revenue of $26.61 million for the quarter, compared to the consensus estimate of $23.36 million. As a group, analysts predict that CytomX Therapeutics will post -0.29 earnings per share for the current year.
Insider Transactions at CytomX Therapeutics
In related news, CEO Sean A. Mccarthy sold 20,223 shares of the business's stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.09, for a total transaction of $42,266.07. Following the transaction, the chief executive officer now owns 524,481 shares in the company, valued at approximately $1,096,165.29. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders sold 35,024 shares of company stock worth $73,200. Company insiders own 7.00% of the company's stock.
Hedge Funds Weigh In On CytomX Therapeutics
Large investors have recently made changes to their positions in the business. AlphaMark Advisors LLC increased its position in CytomX Therapeutics by 119.8% during the 4th quarter. AlphaMark Advisors LLC now owns 23,183 shares of the biotechnology company's stock valued at $36,000 after buying an additional 12,635 shares in the last quarter. Congress Park Capital LLC grew its stake in shares of CytomX Therapeutics by 112.8% in the fourth quarter. Congress Park Capital LLC now owns 239,300 shares of the biotechnology company's stock worth $371,000 after acquiring an additional 126,850 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of CytomX Therapeutics by 737.4% during the third quarter. Bank of New York Mellon Corp now owns 266,836 shares of the biotechnology company's stock valued at $344,000 after acquiring an additional 234,970 shares in the last quarter. 67.77% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. StockNews.com downgraded shares of CytomX Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, April 23rd. JPMorgan Chase & Co. raised CytomX Therapeutics from an "underweight" rating to a "neutral" rating in a research report on Monday, April 22nd.
Check Out Our Latest Report on CytomX Therapeutics
About CytomX Therapeutics
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
